Pulmonx Stock Forecast, Price & News

-1.04 (-2.59 %)
(As of 08/3/2021 05:20 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume341,570 shs
Average Volume348,598 shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive LUNG News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

Pulmonx logo

About Pulmonx

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.22 out of 5 stars

Medical Sector

307th out of 1,309 stocks

Surgical & Medical Instruments Industry

33rd out of 121 stocks

Analyst Opinion: 3.3Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Pulmonx (NASDAQ:LUNG) Frequently Asked Questions

Is Pulmonx a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pulmonx stock.
View analyst ratings for Pulmonx
or view top-rated stocks.

What stocks does MarketBeat like better than Pulmonx?

Wall Street analysts have given Pulmonx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pulmonx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pulmonx?

Pulmonx saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,220,000 shares, an increase of 26.0% from the June 15th total of 968,000 shares. Based on an average daily volume of 455,100 shares, the days-to-cover ratio is currently 2.7 days. Currently, 5.7% of the company's stock are short sold.
View Pulmonx's Short Interest

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) posted its quarterly earnings results on Monday, May, 3rd. The company reported ($0.34) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.05. The company had revenue of $9.24 million for the quarter, compared to analyst estimates of $8.18 million.
View Pulmonx's earnings history

What guidance has Pulmonx issued on next quarter's earnings?

Pulmonx updated its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $49 million-$51 million, compared to the consensus revenue estimate of $49.20 million.

What price target have analysts set for LUNG?

7 brokerages have issued 1 year price objectives for Pulmonx's shares. Their forecasts range from $50.00 to $72.00. On average, they expect Pulmonx's stock price to reach $57.71 in the next twelve months. This suggests a possible upside of 47.3% from the stock's current price.
View analysts' price targets for Pulmonx
or view top-rated stocks among Wall Street analysts.

Who are Pulmonx's key executives?

Pulmonx's management team includes the following people:
  • Mr. Glendon E. French, CEO, Pres & Director (Age 59, Pay $626.82k)
  • Mr. David A. Lehman, Gen. Counsel & Sec. (Age 60, Pay $147.08k)
  • Mr. Geoffrey Beran Rose, Chief Commercial Officer (Age 48, Pay $391.52k)
  • Dr. Derrick Sung, Chief Financial Officer (Age 48)
  • Mr. Sri Radhakrishnan, Chief Technical Officer
  • Mr. Martin Schneider, VP of Fin. and Admin. (Age 61)
  • Ms. Lauren Cristina, VP of Fin. & Admin. (U.S.)
  • Mr. Jérôme Erath, Sr. VP & GM of Europe Middle-East & Africa
  • Mr. David M. Renzi, Sr. VP of Sales - North America (Age 63)

Who are some of Pulmonx's key competitors?

When did Pulmonx IPO?

(LUNG) raised $100 million in an IPO on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Pulmonx's stock symbol?

Pulmonx trades on the NASDAQ under the ticker symbol "LUNG."

Who are Pulmonx's major shareholders?

Pulmonx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (0.09%), Alliancebernstein L.P. (0.08%), New York State Common Retirement Fund (0.06%), Handelsbanken Fonder AB (0.03%), Arizona State Retirement System (0.01%) and Siguler Guff Advisers LLC (0.00%). Company insiders that own Pulmonx stock include Daniel P Florin, Derrick Sung, Geoffrey Beran Rose, Glendon E French III and Scientific Corp Boston.
View institutional ownership trends for Pulmonx

Which institutional investors are selling Pulmonx stock?

LUNG stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have sold Pulmonx company stock in the last year include Derrick Sung, Geoffrey Beran Rose, Glendon E French III, and Scientific Corp Boston.
View insider buying and selling activity for Pulmonx
or view top insider-selling stocks.

Which institutional investors are buying Pulmonx stock?

LUNG stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Handelsbanken Fonder AB, Arizona State Retirement System, New York State Common Retirement Fund, and Siguler Guff Advisers LLC.
View insider buying and selling activity for Pulmonx
or or view top insider-buying stocks.

How do I buy shares of Pulmonx?

Shares of LUNG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulmonx's stock price today?

One share of LUNG stock can currently be purchased for approximately $39.19.

How much money does Pulmonx make?

Pulmonx has a market capitalization of $1.42 billion and generates $32.73 million in revenue each year. The company earns $-32,230,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis.

How many employees does Pulmonx have?

Pulmonx employs 220 workers across the globe.

What is Pulmonx's official website?

The official website for Pulmonx is

How can I contact Pulmonx?

The company can be reached via phone at 650-364-0400 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.